MET Inhibitors Active in Advanced NSCLC

(MedPage Today) -- About half of patients with advanced non-small cell lung cancer (NSCLC) associated with a type of MET anomaly achieved durable responses with the MET inhibitor tepotinib, a multicenter open-label trial showed.
By independent...